Suppr超能文献

澳大利亚慢性阻塞性肺疾病成年患者的支气管扩张剂可逆性

Bronchodilator reversibility in Australian adults with chronic obstructive pulmonary disease.

作者信息

Reid D W, Soltani A, Johns D P, Bish R, Williams T J, Burns G P, Walters E H

机构信息

Department of Respiratory Medicine and Monash Medical School, Alfred Hospital, Commercial Road, Melbourne, Victoria, Australia.

出版信息

Intern Med J. 2003 Dec;33(12):572-7. doi: 10.1111/j.1445-5994.2003.00485.x.

Abstract

BACKGROUND AND AIMS

Bronchodilator reversibility (BDR) and inhaled corticosteroid (ICS) use were assessed for volunteers who responded to an advertisement requesting current or ex-smokers who were experiencing breathlessness to attend for lung function testing.

METHODS

One hundred and fifty-four volunteers responded. Forced expiratory volume (FEV1) was measured before and after 400 microg of salbutamol. Significant BDR was assessed according to guidelines of: (i) the American Thoracic Society (> or =12% plus 200 mL of baseline FEV1 or forced vital capacity), (ii) the British-Thoracic Society (BTS) (> or =15% plus 200 mL of baseline FEV1), (iii) the European Thoracic Society (> or =10% predicted FEV1), and (iv) the most commonly used criteria in Australia and New Zealand (> or =15% of baseline FEV1).

RESULTS

One hundred and twenty-three subjects (33 female; 40 current smokers; median pack years 48 (range 5-144)) were suitable for analysis (i.e. had no history of asthma, demonstrable airflow limitation and a forced expiratory ratio (FER) of <70%). Twenty (16%) patients had an FEV1 within the normal range but FER of <70%, 24 (20%) patients had mild disease (FEV1 60-80% predicted), 31 (24%) patients had moderate disease (FEV1 40-59% predicted), and 48 (39%) patients had severe disease (FEV1 <40% predicted), according to BTS criteria. Significant BDR was evident in: (i) 58 (47%) subjects by American criteria, (ii) 26 (21%) subjects by British criteria, (iii) 19 (15%) subjects by European criteria and (iv) 36 (29%) subjects by Australasian criteria. ICS use was reported by 71 (58%) subjects overall and was weakly, but significantly, related to poorer FEV1 (r = -0.2; P < 0.01), and greater BDR (r = 0.3; P < 0.005).

CONCLUSION

Chronic obstructive pulmonary disease in Australian volunteers with no history of asthma encompasses many individuals with significant BDR. Interestingly, most volunteers reported ICS use and this was related to poorer spirometry and greater BDR. However, until the underlying immuno-pathology has been determined they cannot be assumed to have "asthma" or even an "asthmatic element".

摘要

背景与目的

对于那些回应广告前来参加肺功能测试的现吸烟者或已戒烟者且有呼吸急促症状的志愿者,评估其支气管扩张剂可逆性(BDR)及吸入性糖皮质激素(ICS)的使用情况。

方法

154名志愿者做出回应。在使用400微克沙丁胺醇前后测量用力呼气量(FEV1)。根据以下指南评估显著的BDR:(i)美国胸科学会(基线FEV1或用力肺活量增加≥12%加200毫升),(ii)英国胸科学会(BTS,基线FEV1增加≥15%加200毫升),(iii)欧洲胸科学会(预测FEV1增加≥10%),以及(iv)澳大利亚和新西兰最常用的标准(基线FEV1增加≥15%)。

结果

123名受试者(33名女性;40名现吸烟者;吸烟包年数中位数为48(范围5 - 144))适合分析(即无哮喘病史、无明显气流受限且用力呼气比率(FER)<70%)。根据BTS标准,20名(16%)患者的FEV1在正常范围内但FER<70%,24名(20%)患者患有轻度疾病(FEV1为预测值的60 - 80%),31名(24%)患者患有中度疾病(FEV1为预测值的40 - 59%),48名(39%)患者患有重度疾病(FEV1<预测值的40%)。显著BDR在以下情况中明显:(i)根据美国标准有58名(47%)受试者,(ii)根据英国标准有26名(21%)受试者,(iii)根据欧洲标准有19名(15%)受试者,以及(iv)根据澳大利亚和新西兰标准有36名(29%)受试者。总体上71名(58%)受试者报告使用了ICS,且与较差的FEV1(r = -0.2;P < 0.01)及更大的BDR(r = 0.3;P < 0.005)呈弱但显著的相关性。

结论

在无哮喘病史的澳大利亚志愿者中,慢性阻塞性肺疾病包括许多有显著BDR的个体。有趣的是,大多数志愿者报告使用了ICS,且这与较差的肺功能测定结果及更大的BDR相关。然而,在确定潜在的免疫病理学之前,不能假定他们患有“哮喘”甚至有“哮喘成分”。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验